Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?
Key result
Aspirin at doses of at least 30 mg/day prevents only 13% of serious vascular complications in patients with prior transient ischaemic attack or nondisabling ischaemic stroke.
Why the study?
Does aspirin prevent serious vascular complications in patients with a transient ischaemic attack or nondisabling ischaemic stroke?
Population
Patients who have had a transient ischaemic attack or nondisabling ischaemic stroke of presumed arterial…
Comparison
Aspirin (at least 30 mg/day) vs Without treatment
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Aspirin offers modest secondary prevention; leaves open need for superior regimens after TIA or nondisabling stroke.
Structured PICO
Does aspirin prevent serious vascular complications in patients with a transient ischaemic attack or nondisabling ischaemic stroke?
P
Population
Patients with a history of transient ischaemic attack or nondisabling ischaemic stroke of presumed arterial origin.
I
Intervention
Aspirin (at least 30 mg/day)
C
Comparator
Without treatment
O
Outcome
Serious vascular complications (death from all vascular causes, non-fatal stroke, or non-fatal myocardial infarction)composite
Main Result
Effect estimate: 13% reduction
Aspirin provides only a limited degree of protection (13% reduction) against serious vascular complications in patients with prior TIA or nondisabling ischemic stroke.
Cite This Study
Algra et al. (1999) conducted a review in Transient ischaemic attack or nondisabling ischaemic stroke. Aspirin vs. No treatment was evaluated on Serious vascular complications (death from all vascular causes, non-fatal stroke, or non-fatal myocardial infarction) (13% reduction). Aspirin at doses of at least 30 mg/day prevents only 13% of serious vascular complications in patients with prior transient ischaemic attack or nondisabling ischaemic stroke.